F. Scaglione et al., EFFICACY AND SAFETY OF THE STANDARDIZED GINSENG EXTRACT G-115 FOR POTENTIATING VACCINATION AGAINST COMMON COLD AND OR INFLUENZA SYNDROME/, Drugs under experimental and clinical research, 22(2), 1996, pp. 65-72
The aim of the study was to determine the properties of a standardized
extract of ginseng root in inducing a higher immune response in vacci
nation against influenza. Attention was also paid to the common cold i
n this multicentre, two-arm, randomized, placebo-controlled, double-bl
ind investigation. A total of 227 volunteers who visited 3 private pra
ctices in Milan received daily oral capsule doses of either placebo (1
13) or 100 mg of standardized ginseng extract Ginsana G 115 (114) for
a period of 12 weeks within which they received an anti-influenza poly
valent vaccination at week 4. As a result, while the frequency of infl
uenza or common cold between weeks 4 and 12 was 42 cases in the placeb
o group, it was only 15 cases in the G115 group, the difference being
statistically highly significant (p < 0.001). Whereas antibody titres
by week 8 rose to an average of 171 units in the placebo group, they r
ose to an average of 272 units in the G115 group (p < 0.0001). Natural
killer (NK) activity levels at weeks 8 and 12 were nearly twice as hi
gh in the G115 group as compared to the placebo group (p < 0.0001). In
all the volunteers, laboratory values of 24 safety parameters showed
no significant differences between the end and the beginning of the 12
-week study in either of the groups. There were only 9 adverse events
in the study, the principal one being insomnia.